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Abstract
Objectives: Females with a lifetime diagnosis of major mood disorder (Bipolar Disorder BD,
Major Depressive Disorder MMD) investigated during the luteal phase of their menstrual cycle and
in a condition of clinical well-being showed higher blood serum concentrations of progesterone and
allopregnanolone compared to healthy controls. Women with BD presented even higher levels
than those affected by MDD. This study attempted to verify, in line with a dimensional approach, if
the possible differences in neurohormonal levels may be directly linked to some syndromal clusters
(dimensions) of the mood spectrum disorders indipendently of diagnosis.
Methods: Premenstrual concentrations of allopregnanolone, THDOC, progesterone, and cortisol
were measured in 3 groups of women: 17 BD and 14 MDD outpatients, and 16 control subjects.
Psychiatric evaluation was performed with the SCID-I interview and the SCI-MOODS-SR
questionnaire. The correlation between steroid levels and mood disorder syndromal cluster (SCI-
MOODS-SR domains and sub-domains) was evaluated by means of analysis of main components
with Varimax rotation and Kaiser's normalization (which provided for inclusion of all components
with an Eigen value >1).
Results: Analysis of the main components evidenced the presence of 3 components: 1) mania, 2)
depression both with mixed component 3) steroid + manic cognitivity and suicidal ideas.
Conclusion: Levels of allopregnanolone and progesterone do not correlate with the association
of the depressive and manic syndromes, but rather with mixed symptomatological aspects, and in
particular with cognitive manic and depressive (with suicidal thoughts) dimensions. Further studies
should be carried out to confirm these findings.
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Introduction
Clinical and preclinical studies have suggested that fluctu-
ations in the peripheral and brain concentrations of pro-
gesterone and its metabolites 3α-hydroxy-5α-pregnan-20-
one (allopregnanolone) and 3α,21-dihydroxy-5α-preg-
nan-20-one (THDOC) might play an important role in
certain pathological conditions characterized by emo-
tional or affective disturbances, including major depres-
sion, anxiety disorders, and schizophrenia [1,2].
Moreover, it has been shown that administration of drugs
having clinical relevance in the treatment of these pathol-
ogies influence the secretion of these hormones [1,2].
In a recent study, in a sample of female patients with a life-
time diagnosis of major mood disorder (Bipolar Disorder
-BD, Major Depressive Disorder -MDD) investigated dur-
ing the luteal phase of their menstrual cycle and in a con-
dition of clinical well-being, we found higher blood
serum concentrations of progesterone and allopregna-
nolone compared to healthy controls. Moreover, women
with BD presented even higher levels than those affected
by MDD [3].
Several studies reported a decrease of allopregnanolone in
the blood [4], or brain liquor [5] of patients with Major
Depression. These studies were all performed on patients
during depressive episodes, whilst on the contrary, our
patients were in a state of well-being. Moreover, the study
carried out by Uzunova [4] reported an increase of plas-
matic allopregnanolone levels after treatment with fluox-
etine or fluvoxamine, which is paralled to the increase in
score at the Hamilton Rating Scale for Depression. In our
study, both subjects treated pharmacologically and drug-
free cases presented differences in blood serum concentra-
tions of steroids versus control subjects.
In the study of Uzunova [4] no tests were performed to
verify whether the increase in allopregnanolone concen-
trations observed was related to a specific symptomato-
logical component.
The aim of our study was to verify whether neuroactive
steroid levels correlate with specific syndromal clusters
present throughout the entire spectrum of mood disor-
ders.
Indeed, a continuum between unipolar and bipolar disor-
ders has been hypothesized [6-10], in order to provide a
"dialectic" point of view between the traditional "catego-
rial" diagnostic approach and a more innovative "dimen-
sional" approach, syndromic clusters throughout the
entire bipolar disorder spectrum, independent of diagnos-
tic subdivision, should be verified to ascentain which are
affected by blood serum levels of neuroactive steroids.
In line with a categorial approach, the possible differences
in neurohormonal levels may be directly linked to the
type of diagnosis (eg. Major Depression, Panic Disorder,
Bipolar Disorder), whilst a dimensional approach may
vary on the basis of syndromal components present in the
"spectrum of disorders" examined.
Materials and Methods
Study design and subjects
The sample of the present article is the same of a previous
paper above cited [3]. Of course, instruments used and
analysis performed for this paper are different. A case-con-
trolled study was performed to compare the plasma con-
centrations of allopregnanolone, THDOC, progesterone,
and cortisol in the premenstrual phase of the menstrual
cycle among three groups of women: outpatients with BD,
outpatients with MDD, and control subjects. The study
was approved by the institutional review board of the
"Università Europea del Mediterraneo" and written
informed consent was obtained from all subjects.
In an attempt to verify which of the various syndromic
mood components showed a tendency to correlate with
blood serum neurosteroid levels, both main components
and blood serum steroid levels were analysed on the basis
of results reported throughout the entire sample at single
domains of the SCI-MOODS-SR rating scale.
The study subjects comprised women of reproductive age
divided into three groups: 17 women with a lifetime diag-
nosis of BD I (n = 4, 23.5%) or II (n = 13, 76.5%) accord-
ing to DSM-IV-TR [11] and in a condition of well-being
without relapse or recurrence during the 3 months prior
to study enrollment; 14 women with a diagnosis of MDD
according to DSM-IV-TR [11] and in a condition of well-
being without relapse or recurrence during the 3 months
prior to study enrollment; and 16 women with no diagno-
sis of lifetime psychiatric disorders and with no family his-
tory of mood disorders or anxiety. Subjects were enrolled
on a consecutive basis on referral to a private psychiatric
practice. Personal and anamnestic characteristics of the
study subjects are shown in Table 1. All participants were
of a similar age. A greater proportion of subjects with a
diagnosis of BD took antipsychotic drugs (70.6%) or
mood stabilizers (52.9%) compared with those affected
by MDD (0 and 0%, respectively), but no signifcant differ-
ences either in the use of selective serotonin reuptake
inhibitor (SSRI) or tricyclic antidepressants or in the pro-
portion of drug-free subjects were apparent between the
two patient groups. Subjects with BD were characterized
by a longer course of illness and had been in psychiatric
care for a longer period of time compared with those with
MDD.Clinical Practice and Epidemiology in Mental Health 2008, 4:3 http://www.cpementalhealth.com/content/4/1/3
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Exclusion criteria included comorbidity with invalidating
physical illnesses or lesser physical disorders (such as
ovarian cysts or immune diseases) that might have
affected steroid hormone concentrations, as well as the
use of drugs (with the exception of psychotropic agents)
that might affect steroid hormone concentrations (such as
contraceptive pills and steroids).
Inclusion criteria included regular menstrual cycles and
the absence of stressful life events during the previous 3
months.
Blood sampling and measurement of steroid 
concentrations
Blood samples were obtained between 0900 and 0930
hours from all study subjects 7 to 10 days before menstru-
ation. All subjects had fasted overnight and had taken
absolutely no drugs during the previous 24 h before blood
collection. Plasma was isolated from the blood speci-
mens, and 1-mL portions were diluted with 2 mL of water
and then subjected to extraction three times with 3 mL of
ethyl acetate. The combined organic phases were dried
under vacuum. Recovery of steroids during extraction was
monitored by the addition of trace amounts of [3H]pro-
gesterone (6000 to 8000 cpm, 52 Ci/mmol) and was
found to be ~90%. Quantitative analysis of steroids was
performed by radioimmunoassay with specific antibodies
and respective tritiated standards as described previously
[12,13]. Antibodies to allopregnanolone and to THDOC
were characterized previously [12] and those to progester-
one and to cortisol were from ICN (Costa Mesa, CA).
Psychiatric assessment
Psychiatric assessment of all subjects was performed by a
psychiatrist trained in the use of the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) [14]. Clin-
ical interviews took place at a private medical practice. All
participants were subjected to a questionnaire concerning
personal and anamnestic details, a self-administered
questionnaire on symptoms of Premenstrual Dysphoric
Disorder (PMDD) according to DSM-IV [15], a structured
clinical interview (SCID-I), and the Structured Clinical
Interview for the Spectrum of Mood Disorders, Self Report
(SCI-MOODS-SR, self-rating questionnaire, lifetime ver-
sion) [16-20]. The SCI-MOODS-SR rating scale comprises
161 items and 4 domains (mood, energy, cognitivity and
rhythmicity), the first 3 of which each have 2 sub-
domains (depressive and manic/hypomanic) [8].
Statistical analysis
Data were analyzed with the SPSS-SP 12.0 software pack-
age (SPSS inc., Chicago Illinois). The correlation between
steroid levels, mood disorders (SCI-MOODS-SR domains
and sub-domains) and premenstrual symptoms was eval-
uated by means of analysis of main components with Var-
imax rotation and Kaiser's normalization (which
provided for inclusion of all components with an Eigen
value >1).
Results
The plasma concentrations of cortisol, progesterone,
3α,5α-THPROG, and 3α,5α-THDOC in patients with BD,
patients with MDD, and control subjects, as presented in
the previous paper [3], are shown in Table 2. The concen-
trations of progesterone and 3α,5α-THPROG differed sig-
nificantly among the three groups, whereas that of 3α,5α-
THDOC showed a tendency to differ. No significant dif-
ference was apparent in the plasma levels of cortisol
among the three groups.
The analysis of main components performed taking as
items frequency of response to SCI-MOODS-SR domains
and cortisol concentrations, allows 3 components
accounting for a total of 70.3% of variance to be identi-
fied. Table 3 illustrates the rotation matrix of components
and reveals how component 1 (33.7% of total variance,
Eigen value 5.9) aggregates SCI-MOODS-SR items:
D1-28, Depressed Mood, (0.92); D58-67, Depressive
Energy, (0.86); D81-98, Depressive Cognitivity, (0.75);
Table 1: Personal and anamnestic characteristics of samples.
Samples Mean Age ± SD Familiarity 
Mood 
disorders
Antipsychotics SSRIs Stabilisers Tricyclic 
drugs
Drug-free Years of Illness 
(mean ± SD)
Years of care 
(mean ± SD)
Comorbidity 
Panic 
Disorder
Comorbidity 
Obsessive-
Compulsive 
Disorder
Comorbidity 
Eating 
Disorder
1. BP 
(N = 17)
37.2 ± 8.0 11 13 10 9 2 2 14.8 ± 5.7 5.9 ± 2.9 9 6 3
2. MDD 
(N = 14)
34.4 ± 8.5 6 0 7 0 1 6 8.9 ± 4.5 2.9 ± 2.5 8 4 4
3. Controls 
(N = 16)
37.1 ± 8.2
F = 0.55, 
(2,44,46 DF)
X2 = 2.3 X2 = 17.9 X2 = 0.7 X2 = 8.0 X2 = 0.1 X2 = 2.4 F = 9.9 F = 9.3 X2 = 0.1 X2 = 0.1 X2 = 0.1
P = 0.58 NS P < 0.0001 NS P < 0.01 NS NS P < 0.01 
(1,29,30 DF)
P < 0.01 
(1,29,30 DF)
NS NS NSClinical Practice and Epidemiology in Mental Health 2008, 4:3 http://www.cpementalhealth.com/content/4/1/3
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D150-161, Rhythmicity, (0.72); D99-108, Depressive
Cognitivity, (0.67); D138-149, Rhythmicity, (0.67); D68-
80, Manic Energy, (0.44); D29-57 (0.39); component 2
(26.7% of variance, Eigen value 3.2) aggregates SCI-
MOODS-SR items: D109-124, Manic Cognitivity, (0.79);
D68-80, Manic Energy, (0.74); D132-137, Rhythmicity,
(0.73); D29-57, Manic Mood (0.70); D125-131, Manic
Cognitivity, (0.69); D81-98, Depressive Cognitivity,
(0.45); D150-161, Rhythmicity, (0.37); D138-149,
Rhythmicity, (0.36); and component 3 (9.8% of total var-
iance, Eigen value1.2) aggregates the level of cortisol
(0.91) with SCI- MOODS-SR item: D99-108, Depressive
Cognitivity, (0.43).
The analysis of main components performed taking as
items frequency of response to SCI-MOODS-SR domains
and progesterone concentrations, allows 3 components
accounting for a total of 71.2% of variance to be identi-
fied. Table 4 illustrates the rotation matrix of components
and reveals how component 1 (49.7% of total variance,
Eigen value 3.9) aggregates SCI-MOODS-SR items: D1-28,
Depressed Mood, (0.91); D58-67, Depressive Energy,
(0.86); D81-98, Depressive Cognitivity, (0.73); D99-108,
Depressive Cognitivity; (0.71); D150-161, Rhythmicity,
(0.67); D138-149, Rhythmicity, (0.65); D29-57, Manic
Mood, (0.37); component 2 (27.6% of variance, Eigen
value 3.3) aggregates SCI- MOODS-SR items: D132-137,
Rhythmicity, (0.75), D125-131, Manic Cognitivity,
(0.73); Manic Energy, D68-80 (0.73); D29-57, Man ic
Mood (0.72); D109-124, Manic Cognitivity, (0.70); D81-
98, Depressive Cognitivity (0.49); D138-149, Rhythmic-
ity, (0.46); D150-161, Rhythmicity, (0.40); and compo-
nent 3 (9.2% of total variance, Eigen value 1.1) aggregates
the level of progestrerone (0.87) with SCI- MOODS-SR
items: D109-124, Manic Cognitivity, (0.52); D99-108
Depressive Cognitivity, (0.31).
The analysis of main components performed taking as
items frequency of response to SCI-MOODS-SR domains
and allopregnanolone concentrations, allows 3 compo-
nents accounting for a total of 71.3% of variance to be
identified. Table 5 illustrates the rotation matrix of com-
ponents and reveals how component 1 (49.7% of total
variance, Eigen value 6.0) aggregates SCI-MOODS-SR
items: D1-28, Depressed Mood, (0.91); D58-67; Depres-
sive Energy, (0.85); D81-98, Depressive Cognitivity,
(0.74); D99-108, Depressive Cognitivity, (0.69); D150-
161, Rhythmicity, (0.68), D138-149, Rhythmicity (0.67),
D68-80; Manic Energy, (0.39); D29-57, Manic Mood
(0.37); component 2 (12.4% of variance, Eigen value 1.5)
aggregates SCI- MOODS-SR items: D132-137, Rhythmic-
ity, (0.74); D68-80, Manic Energy, (0.74); D125-131,
Manic Cognitivity, (0.73), D109-124, Manic Cognitivity
(0.72); D29-57, Manic Mood, (0.71); D81-98, Depressive
Cognitivity, (0.48); D138-149, Rhythmicity, (0.42) and
D150-161, Rhythmicity, (0.39) and component 3 (9.2%
of total variance, Eigen value 1.1) aggregates the level of
allopregnanolone (0.87) with SCI-MOODS-SR items:
D109-124, Manic Cognitivity, (0.50); D99-108, Depres-
sive Cognitivity (0.34).
The analysis of main components performed taking as
items frequency of response to SCI-MOODS-SR domains
and THDOC concentrations, allows 3 components
accounting for a total of 70.4% of variance to be identi-
fied. Table 6 illustrates the rotation matrix of components
and reveals how component 1 (33.4% of total variance,
Eigen value 4.0) aggregates SCI-MOODS-SR items: D1-28,
Depressed Mood, (0.92); D58-67, Depressive Energy
(0.88); D81-98, Depressive Cognitivity. (0.75); D99-108,
Depressive Cognitivity, (0.73); D150-161, Rhythmicity,
(0.68); D138-149, Rhythmicity, (0.64); D68-80, Manic
Energy (0.42); D29-57, Manic Mood (0.38); component 2
(27.2% of variance, Eigen value3.3) aggregates SCI-
MOODS items D132-137, Rhythmicity, (0.76); D68-80,
Manic Energy (0.74); D109-124, Manic Cognitivity,
(0.74); D29-57, Manic Mood, (0.73); D125-131, Manic
Cognitivity, (0.70); D81-98, Depressive Cognitivity
(0.46); D138-149, Rhythmicity, (0.40); and D150-161,
Rhythmicity, (0.37); and component 3 (9.8% of total var-
iance, Eigen value 1.2) aggregates the level of THDOC
(0.87) with SCI- MOODS items D109-124, Manic Cogni-
tivity (0.39).
Table 7 presents a summary of the SCI-MOODS-SR items
which aggregate in each specific "3 component" deriving
from analysis of the main components; it can be observed
how allopregnanolone and progesterone aggregate with
the "manic cognitivity" domain and with the "depressive
cognitivity" sub-domain pertaining to suicidal ideas,
while THDOC aggregates only with the former domain
and cortisol only with the latter.
Discussion
Analysis of the main components at all domains of the
SCI-MOODS-SR rating scale, together with the levels of
cortisol, allopregnanolone, progesterone and THDOC
(each of which introduced singly for a total of four analy-
ses) underlines 3 components, of which the first 2, per-
taining solely to SCI-MOODS-SR items, remain
substantially homogeneous throughout the four analyses
performed for each specific steroid.
The first component is the most representative in terms of
general variability and refers to depressive symptoms
(SCI-MOODS-SR domains D1-28 Depressed Mood; D58-
67 Depressive Energy; D81-98, D99-108 Depressive Cog-
nitivity; D150-161, D138-149 Rhythmicity) but some
manic components are also correlated to it (both Manic
Energy [D68-80] and Manic Mood [D29-57] are relatedClinical Practice and Epidemiology in Mental Health 2008, 4:3 http://www.cpementalhealth.com/content/4/1/3
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by more than r > 0.30 in each of the four analysis). The
second component refers to manic symptoms and aggre-
gates with SCI-MOODS-SR domains D68-80 Manic
Energy; D132-137 Rhythmicity; D125-131, D109-124
Manic Cognitivity; D29-57 Manic Mood; D81-98 Depres-
sive Cognitivity (also this component showed some
"mixed" elements).
The presence of components not associated with "pure"
manic or depressive syndromes seems to confirm the
validity of a unitary approach in the mood spectrum sug-
gested by the findings of a study by Cassano and coll. [8].
This study showed a substantial number of manic/
hypomanic symptoms in patients with recurrent unipolar
depression and indicated that in both patients with recur-
rent unipolar depression and patients with bipolar I disor-
der the number of manic/hypomanic items of SCI-
MOODS interview was related to an increased likelihood
of endorsing suicidal ideation. According to the above
cited results, our findings seem to challenge the tradi-
tional unipolar-bipolar dichotomy and bridge the gap
between these two categories.
Introduction of the "neuroactive steroid" item does not
modify the expected "core" profiles for mood disorders,
depressive component 1 and manic component 2, both
with a "mixed" component, but rather introduces a new
exclusive component. Ultimately, depression or mania
are the main syndromic components which correlate with
neurosteroid concentrations, although manic compo-
nents such as delusions of grandeur and, to a lesser but
statistically significant degree, suicidal thoughts may also
concur. The latter profile is clearly distinguishable for pro-
gesterone and allopregnanolone, cortisol is characterised
by a tendency to correlate with manic components (whilst
it actually correlates with depression) and THDOC corre-
lates with manic ideas alone, rendering interpretation of
this finding rather complicated. Should the hypothesis of
a relationship between blood serum concentrations and
clinical improvment of depressive symptomatology be
confirmed, it may provide an explanation for the associa-
tion with manic ideas, although it would not justify the
association (albeit slight) with depressive ideas, particu-
larly with the series of SCI-MOODS-SR items concerned
with suicidal thoughts.
Similar to antidepressants, neurosteroids may possibly
associate with improvement of syndromic components of
"pure" forms of depression, but not with improvement of
"mixed"states in which components such as suicidal ideas
and delusions of grandeur frequently co-exist [21].
With regard to blood serum concentrations of cortisol, the
possible existence of two distinct psychoneuroendocrino-
Table 2: Plasma concentrations of steroids (ng/mL) among patients with bipolar disorder (BP), patients with major depressive 
disorder (MDD), and control subjects.
Steroid BD MDD Controls F (2, 44, 46) P Bonferron BD vs Cs 
t Sstudent 44DF
Bonferroni BD vs 
MDD t Sstudent 
44DF
Bonferroni MDD vs 
Cs t Sstudent 44DF
Cortisol 127.7 ± 40.4 116.8 ± 54.2 108.4 ± 37.2 0.80 0.456 1.2. 0.5 0.1
Progesterone 11.0 ± 2.6 4.0 ± 3.6 1.0 ± 1.1 64.9 <0.0001 11.0, P < 0.0001 7.0, P < 0.001 3.2, P < 0.0001
3α,5α THPROG 9.6 ± 2.3 5.1 ± 1.2 2.1 ± 0.8 91.7 <0.0001 13.4, P < 0.001 7.7, P < 0.0001 3.2, P < 0.001
3α,5α-THDOC 2.1 ± 3.0 1.1 ± 0.4 0.6 ± 0.4 2.8 0.073 2.1 0.4 0.1
Table 3: Rotation matrix of SCI-MOODS-SR components/cortisol (analysis of main components with Varimax rotation and Kaiser's 
normalization)
SCI-MOODS-SR DOMAIN Item Component 1 Component 2 Component 3
Depressed Mood D1-28 0.92 0.16 0.08
Manic Mood D29-57 0.39 0.70 0.13
Depressive Energy D58-67 0.86 0.13 0.16
Manic Energy D68-80 0.44 0.74 0.03
Depressive Cognitivity D81-98 0.75 0.45 0.10
Depressive Cognitivity D99-108 0.67 0.10 0.43
Manic Cognitivity D109-124 -0.02 0.79 0.27
Manic Cognitivity D125-131 0.16 0.69 0.00
Rhythmicity D132-137 0.32 0.73 -0.13
Rhythmicity D138-149 0.67 0.36 -0.03
Rhythmicity D150-161 0.72 0.37 0.13
Cortisol 0.11 0.09 0.91Clinical Practice and Epidemiology in Mental Health 2008, 4:3 http://www.cpementalhealth.com/content/4/1/3
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logical profiles for depressive disorders has been hypoth-
esized [22], the first characterized by hypercortisolemia
and depressive melancholy, the second by hypocortiso-
lemia and atypical depression.
The findings of the present study do not provide evidence
to support this hypothesis; however, on assuming the
presence of marked suicidal ideas in melancholy depres-
sion, it is feasible to maintain that a higher frequency of
increased cortisol levels may have determined an associa-
tion between this steroid and suicidal ideas. Moreover,
atypical forms of depression would appear to be more fre-
quent among subjects with bipolar disorders [23] and
unlike allopregnanolone and progesterone, cortisol does
not present higher levels in BD than in MDD subjects.
Study limitations
Small sample size
The SCI-MOODS is an instrument that explores lifetime
symptoms, while the neurosteroids concentrations are
cross-sectional. As a consequence, the neurohormonal
levels found performing the study 7 to 10 days before
menstruation (a single observation per woman) are
linked with syndromal clusters of lifetime mood spec-
trum. A study testing more than a single menstrual phase
during a longer observational period should be carried
out.
Conclusion
Levels of allopregnanolone and progesterone do not cor-
relate with association of the depressive and manic syn-
dromes, but rather with "mixed" symptomatological
aspects, and in particular with cognitive manic and
depressive (with suicidal thoughts) dimensions.
The specific symptomatological areas involved may
indeed suggest the involvement of an endogenous mech-
anism similar, at least in part, to that implicated for anti-
depressive drugs. The data obtained in our study do not
appear to exclude the possibility that an increase in neu-
Table 4: Rotation matrix of SCI-MOODS-SR components/progesterone (analysis of main components with Varimax rotation and 
Kaiser's normalization)
SCI-MOODS-SR DOMAIN Item Component 1 Component 2 Component 3
Depressed Mood D1-28 0.91 0.21 0.04
Manic Mood D29-57 0.37 0.72 0.10
Depressive Energy D58-67 0.86 0.13 0.22
Manic Energy D68-80 0.39 0.73 0.24
Depressive Cognitivity D81-98 0.73 0.49 0.06
Depressive Cognitivity D99-108 0.71 0.08 0.31
Manic Cognitivity D109-124 -0.05 0.70 0.52
Manic Cognitivity D125-131 0.13 0.73 -0.07
Rhythmicity D132-137 0.27 0.75 0.07
Rhythmicity D138-149 0.65 0.46 -0.24
Rhythmicity D150-161 0.67 0.40 0.09
Progesterone 0.24 0.09 0.87
Table 5: Rotation matrix of SCI-MOODS-SR components/allopregnanolone (analysis of main components with Varimax rotation and 
Kaiser's normalization)
SCI-MOODS-SR DOMAIN Item Component 1 Component 2 Component 3
Depressed Mood D1-28 0.91 0.19 0.08
Manic Mood D29-57 0.37 0.71 0.12
Depressive Energy D58-67 0.85 0.13 0.21
Manic Energy D68-80 0.39 0.74 0.22
Depressive Cognitivity D81-98 0.74 0.48 0.06
Depressive Cognitivity D99-108 0.69 0.08 0.34
Manic Cognitivity D109-124 -0.05 0.72 0.50
Manic Cognitivity D125-131 0.15 0.73 -0.16
Rhythmicity D132-137 0.28 0.74 0.06
Rhythmicity D138-149 0.67 0.42 -0.20
Rhythmicity D150-161 0.68 0.39 0.10
Allopregnanolone 0.25 0.07 0.87Clinical Practice and Epidemiology in Mental Health 2008, 4:3 http://www.cpementalhealth.com/content/4/1/3
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rosteroid levels may be related to improvement of the
clinical picture.
Further studies should be carried out to confirm these
findings and to ascertain whether fluctuations observed in
neurosteroid levels may be in some way related to the
cyclicity of the bipolar spectrum, particularly to the pre-
vailing of several syndromic components. To this regard,
studies aimed at further investigating the role of neuros-
teroids in mood disorders could lead to the opening of
new therapeutic frontiers.
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